Background: Seizures in neonates are relatively common, and are strong predictors of long-term cognitive and developmental impairment like cerebral palsy. Current anti-seizure therapies (phenobarbitone (pheno)) can be neurotoxic. We propose that ganaxolone (ganax), a GABA A agonist, will reduce seizures, and reduce markers of brain injury following hypoxia ischemia (HI). We investigated the effects of ganax or pheno on seizure burden and neuropathology in HI lambs. Methods: HI was induced via umbilical cord occlusion in term lambs (n = 21; sham n = 7). HI lambs were treated with either ganax (5 mg/kg/bolus followed by 5 mg/kg/d for 2 days) or pheno (20mg/kg/bolus followed by 5 mg/kg/day for 2 days) at 6 h. Seizure burden was assessed using continuous amplitudeintegrated electroencephalogram (aEEG) recording. At 48 h, lambs were euthanized for brain collection and analysis of neuropathology.
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Methods: HI was induced via umbilical cord occlusion in term lambs (n = 21; sham n = 7). HI lambs were treated with either ganax (5 mg/kg/bolus followed by 5 mg/kg/d for 2 days) or pheno (20mg/kg/bolus followed by 5 mg/kg/day for 2 days) at 6 h. Seizure burden was assessed using continuous amplitudeintegrated electroencephalogram (aEEG) recording. At 48 h, lambs were euthanized for brain collection and analysis of neuropathology.
Results: At birth, HI lambs had a pH <7.0 and blood pressure was reduced to 16.4 AE 1.2 mmHg, indicating severe birth asphyxia. All HI lambs demonstrated electrographic seizures; mean number of seizures/h (6-12 h) was 4.8 AE 2.2. Ganax treatment reduced the number of seizures to 1.0 AE 0.9/h compared to pheno (3.2 AE 1.6/ h) (P = 0.02). Brain histology revealed improved neuronal survival (NeuN+ cell number) and reduced cell death (TUNEL+) in the cortex and basal ganglia after ganax treatment, compared to pheno (P = 0.048 and P = 0.03), respectively.
Conclusions: Ganax treatment in lambs with HI decreased seizure activity, improved neuronal survival and reduced cell death. Ganax has a high margin of safety and proved to be a better therapy. Methods: After screening 1095 studies, random effects meta-analysis was conducted in 25 case-control published studies comparing standardized cognitive and motor developmental tests in POE and drug-free (control, C) children between 6 months to 18 years of age. All types of opioid exposure were included. Main outcome measure was standardized mean difference (SMD) in age-appropriate cognitive and physical development tests.
COGNITIVE AND MOTOR OUTCOMES OF CHILDREN
Results: Children were born between 1974 and 2007. Cognitive outcomes were compared for three age groups: 0-2 (POE: 584, C: 1496), 2-6 (POE: 719, C: 1346) and 6-18 (POE: 152, C: 140) years. Motor outcomes were compared for children up to 6 years old (POE: 688, C: 1500). SMD (95% Confidence Interval) were 0.52 (0.31-0.74)*, 0.38 (0.07-0.69)* and 0.44 (-0.28 -1.16) lower in cognitive tests for POE children at 0-2, 2-6 and 6-18 years. Motor scores were 0.49 (0.23-0.74)* lower in POE children.
*P<0.05 Conclusions: POE is negatively associated with neurocognitive and physical development that are apparent from 6 months of age and persist until adolescence. The exact cause and the relationship of these findings with other factors are unclear but suggest that children with POE should be provided with long-term support and intervention beyond infancy. Background: There are limited and inconsistent data suggesting that mild iodine deficiency in pregnancy may be associated with poorer neurodevelopmental outcomes in children. This study examined the relationship between maternal iodine intake in pregnancy and childhood neurodevelopment.
MATERNAL IODINE INTAKE IN PREGNANCY AND CHILDHOOD NEURODEVELOPMENT AT 18 MONTHS
Methods: We conducted a pregnancy cohort study with 699 mother and child pairs. Exposures were maternal iodine intake and urinary iodine concentration (UIC) assessed at enrolment (<20 weeks' gestation) and at 28 weeks' gestation. Main outcome measure was childhood neurodevelopment assessed at 18 months using Bayley Scales of Infant and Toddler Development (Bayley-III).
Results: Mean (SD) composite Bayley-III scores of the children were 96.7 (11.6), 94.5 (17.8) and 99.4 (10.6 ) for the cognitive, language and motor scales, respectively. Maternal iodine intake in the lowest (< 220 μg/day) and highest (≥391 μg/day) quartiles was associated with lower cognitive, language and motor scores [mean difference (95% CI) ranged from 2.4 (0.01, 4.8) to 7.0 (2.8, 11.1) points lower] compared with mothers with an iodine intake in the middle quartiles, with or without adjustment for key covariates including maternal IQ, education and home environment. There was no association between UIC in pregnancy and Bayley-III outcomes regardless of whether UIC and the outcomes were analysed as continuous or category variables.
Conclusions: Both low and high iodine intakes in pregnancy were associated with poorer childhood neurodevelopment in this iodine sufficient population. Further research is needed to determine the optimal level of iodine intake, and to identify pregnant women most at risk of iodine depletion for intervention.
